Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mark Strobeck is President and CEO at Rockwell Medical. OQRO lists 4 transactions filed with the SEC under this name, the latest on Jul 3, 2025, each linked to the official Form 4.
President and CEO
Disclosures on record
4
Companies involved
1
Rockwell MedicalRMTI
4 disclosures · Oct 2024 – Jul 2025 · 4 sold
Jul 1, 2025Sold~$5.7Kdisclosed Jul 3
DetailsOfficial recordApr 1, 2025Sold~$7.5Kdisclosed Apr 2
DetailsJan 2, 2025Sold~$4.4Kdisclosed Jan 6
DetailsOfficial recordOct 1, 2024Sold~$8Kdisclosed Oct 3
DetailsOfficial recordMark Strobeck has no open-market purchase on record since 2024. Sales in 2 of the 3 years since 2024.
Mark Strobeck reported 0 open-market purchases and 4 sales since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $18K3×3 trades |
| 2024 | — | $8K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Mark Strobeck reported holding 61,349 shares of Rockwell Medical (RMTI), worth about $357K at the last close of $6 (Nov 20, 2026).
Rockwell Medical's proxy statement reports total compensation of $1.9M for its chief executive for fiscal year 2025, after $1.31M for 2024. Mark Strobeck files with the SEC as President and CEO of Rockwell Medical. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 30, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Rockwell Medical RMTI | 61,349 | 61K direct | $6 | $357K | Oct 1, 2026 |
Is this Mark Strobeck’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 1, 2026, Mark Strobeck reported holding 61,349 shares of Rockwell Medical (RMTI). At the last close of $6 on Nov 20, 2026, that is about $357K. This is the stake disclosed in filings, not a net worth.
No public filing gives Mark Strobeck's net worth. What SEC Form 4 shows is the stock stake: 61,349 shares of Rockwell Medical (RMTI), about $357K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Rockwell Medical's proxy statement reports total compensation of $1.9M for its chief executive for fiscal year 2025, after $1.31M for 2024. Mark Strobeck files with the SEC as President and CEO of Rockwell Medical. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Mark Strobeck has no open-market purchase on record since 2024. Sales in 2 of the 3 years since 2024.
In SEC filings since 2024: no open-market purchase is on record; the latest open-market sale is from 2025.
Rockwell Medical (RMTI), from 2024 to 2025: 0 purchases and 4 sales.
Mark Strobeck reported 0 open-market purchases and 4 sales here, 2024 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.